NIHR Funding and Support Round-up |  NIHR  |  6 September 2018

Including  >>>

Latest funding opportunities

Have your say: trial registration and timely disclosure of results

New investigators can’t apply for research funding…can they? | By Justine Tomlinson

Hear Professor Jeremy Wyatt explain why the NIHR is seeking to fund more research into digital health, and what kind of proposals we would like to see.

What are studies within a trial (SWAT)?

From the RDS desk… Read More NIHR Funding and Support Round-up |  NIHR  |  6 September 2018

The Big Trends Transforming Pharma | 28 August | eyeforpharma

Read the article here to hear from:

Sebastian Guth, Executive Vice President and Chief Marketing Officer, Bayer

Christi Shaw, Senior Vice President and President, Lilly Bio Medicines, Eli Lilly

Kris Sterkens, Company Groups Chairman, Europe, Middle East and Africa, Janssen

Julie Gerberding, EVP & Chief Patient Officer, MSD

Jim Robinson, President & COO, Alkermes

Andrin Oswald, Director of Life Sciences Partnerships, Global Health, Gates Foundation… Read More The Big Trends Transforming Pharma | 28 August | eyeforpharma

NIHR Life Sciences Industry Newsletter |  NIHR  |  30 August 2018

Record numbers take part in life sciences industry research

New recorded webinar: Our offer to the life sciences

Companies should bring their biosimilar studies to the UK. Here’s why…

NIHR partners with the British Heart Foundation in world-leading cardiovascular research

Transparent and consistent costing approach for commercial contract research

Improving CRN research activity data collection… Read More NIHR Life Sciences Industry Newsletter |  NIHR  |  30 August 2018

STAT: First Opinion |A week’s worth of perspectives by experts on science & medicine | Curated by Patrick Skerrett | 29 July

Blockchains for biomedicine and health care are coming. Buyer: be informed | By ANDY CORAVOS AND NOAH ZIMMERMAN

Are embryos people? The answer will determine the future of reproductive medicine | By ERIC J. FORMAN

A tax on medical devices makes no sense. It’s time to eliminate it for good |  By DAVID BEIER… Read More STAT: First Opinion |A week’s worth of perspectives by experts on science & medicine | Curated by Patrick Skerrett | 29 July

BioPharma Dive: Marketing | July 18 | AbbVie delays another Humira rival | PhRMA proposes rebate shake-up

Top Marketing News

How molecular biomarkers are transforming cancer treatment

AbbVie goes 3-0 in delaying Humira rivals

Drug lobby aims to shake up how medicines are paid for

Where does J&J’s new drug fit in the crowded HIV market?
5 drugs to watch as biotechs report Q2

FDA seeks to make more drugs available over the counter

Gilenya patent decision gives MS market a reprieve… Read More BioPharma Dive: Marketing | July 18 | AbbVie delays another Humira rival | PhRMA proposes rebate shake-up

Im-patient UPDATE  >>>  By POPULAR DEMAND We’re now going to North America

If you’re from North America 
and have an idea, or suggestion, that you would like to be put forward for consideration towards the Conference agenda or Conference Design, then we would love to hear from you.  Maybe you’d even like to get more involved!

You can let us know by filling out the survey via the following link  :-)… Read More Im-patient UPDATE  >>>  By POPULAR DEMAND We’re now going to North America